10-KPeriod: FY2024

Philip Morris International Inc. Annual Report, Year Ended Dec 31, 2024

Filed February 6, 2025For Securities:PM

Summary

Philip Morris International Inc. (PM) reported robust growth in its smoke-free product portfolio, driven by the strong performance of IQOS and ZYN brands, which continues to be a key driver of the company's transformation. Net revenues increased by 7.7% to $37.9 billion, with smoke-free products contributing significantly to this growth. Despite a notable impairment charge of $2.3 billion related to its investment in Rothmans, Benson & Hedges Inc. (RBH), the company demonstrated resilience, with operating income increasing by 16.0% year-over-year. PMI's strategic focus on a smoke-free future is evident in its continued investment in R&D and commercialization of these products. The company is navigating a complex regulatory and economic landscape, including inflationary pressures and geopolitical events, but maintains a strong financial position with significant cash flows from operations and ample liquidity.

Financial Highlights

50 data points
Beta

Revenue

$37.88B

64.8% Gross Margin

Net Income

$7.06B

18.6% Net Margin

EPS (Diluted)

$4.52

Total Assets

$61.78B

Cash & Equivalents

$4.25B

Free Cash Flow

$10.77B

Financial Statements
Beta
Revenue$37.88B
Cost of Revenue$13.33B
Gross Profit$24.55B
R&D Expenses$759.00M
Operating Income$13.40B
Net Income$7.06B
EPS (Basic)$4.53
EPS (Diluted)$4.52
Shares Outstanding (Basic)1.55B
Shares Outstanding (Diluted)1.56B

Key Highlights

  • 1Net revenues increased by 7.7% to $37.9 billion, driven by strong performance in smoke-free products and favorable pricing.
  • 2Operating income rose by 16.0% year-over-year, demonstrating the company's ability to manage costs and leverage growth.
  • 3A significant impairment charge of $2.3 billion related to the RBH equity investment impacted diluted EPS, resulting in a decrease from $5.02 in 2023 to $4.52 in 2024.
  • 4Shipment volume for heated tobacco units (HTUs) increased by 11.6%, and oral SFP volume (primarily ZYN nicotine pouches) grew by 27.8%, highlighting the success of PMI's smoke-free transition.
  • 5The company is progressing with its smoke-free product manufacturing capacity expansion, including investments in ZYN capacity in the U.S.
  • 6PMI continues to actively manage its debt, reducing total debt by $2.2 billion to $45.7 billion and maintaining strong liquidity with $4.2 billion in cash and cash equivalents.
  • 7The company's commitment to returning capital to shareholders is demonstrated by $8.2 billion in dividends paid in 2024, including a 3.8% increase in the quarterly dividend.

Frequently Asked Questions

Philip Morris International's revenue growth was primarily driven by its smoke-free products, with significant contributions from the IQOS and ZYN brands. Favorable pricing, particularly in combustible tobacco, and an increase in smoke-free product volumes also played a key role.

The impairment charge of $2.3 billion related to Philip Morris International's investment in Rothmans, Benson & Hedges Inc. (RBH) significantly impacted the company's diluted earnings per share for 2024, reducing it by $1.49. While this is a substantial non-cash charge, the underlying business operations showed strong growth.

PMI is advancing its 'smoke-free future' strategy through substantial investment in the development, scientific substantiation, and commercialization of smoke-free products, such as IQOS (heated tobacco) and ZYN (oral nicotine pouches). The company is expanding its manufacturing capacity for these products and actively promoting consumer switching from cigarettes.

For the full year 2025, PMI expects smoke-free product shipment volume growth of 12% to 14%, with a specific expectation for U.S. nicotine pouch shipment volume to reach 780 to 820 million cans. This indicates continued strong momentum in the transition to smoke-free alternatives.